Governments worldwide have committed to a UN strategy pledging to end the HIV epidemic by 2030. Achieving these global targets will require unprecedented investment to drive continued progress. However, global economic realities prompt concern: international HIV assistance is highly uncertain, and donor HIV related disbursements have declined, making the implementation of HIV prevention strategies that are efficient and affordable especially critical. This paper provides a commentary of Cremin et al.,(2017)’s contribution to the evidence highlighting the importance of considering the cost efficiency and affordability of HIV prevention resources in the context of current resource constraints. Overall, the paper highlights the importance of not only relying on local costs data but also putting findings in the context of local HIV budgets, particularly given limited and unreliable funding.
Evidence confirms the extraordinary progress in realising the individual and public health benefits of antiretroviral therapy.1,2 Governments worldwide have committed to a UN strategy pledging to end the HIV epidemic by 2030.3 The intensive treatment-as-prevention response will require equally strong coordination with robust behavioral and biomedical prevention strategies, such as condom promotion programming, voluntary medical male circumcision, and pre-exposure antiretroviral prophylaxis (PrEP).
Citation: Kimmel AD, Nash D. HIV prevention resources: time to move toward affordability. Lancet HIV. 2017 Feb 20. pii: S2352-3018(17)30022-X. doi: 10.1016/S2352-3018(17)30022-X. [Epub ahead of print] Link to PubMed >>